respectively. In patients with ILD, CT scan & FVC were compared at baseline & 12 months.

Results: 29 patients (seropositive 28 (RF/Anti CCP/BOTH+VE), seronegative 1) were given RTX for RA over a 2-year period of which 12 had CD19, CD20 & IgG tested. Mean SDAI reduction from baseline to 6 months post treatment was 30%, 32% & 14% while complete remission (SDAI<3.3) was attained in 100%, 18% & 20% in DMARD naïve, DMARD resistant & ILD groups, respectively. CD19, CD20 & IgG reduced from 18.6%, 18.4% & 18.53g/L to 3.7%, 3.7% & 9.7g/L respectively FVC improved from 62.4% to 67% at 12. The percentage of patients with lung involvement >20% reduced from 53.3% to 46.7%. Flare was observed in one patient who received 500mg RTX. CD19, CD20 & IgG levels increased from 7.9%, 8% & 9.8g/L to 27%, 25% & 13g/L respectively. 3 patients in the 1g group were followed up at 12, 18 & 24 months. In these patients there were no flares or worsening symptoms. 1 patient was double negative for RF & Anti CCP and this patient did not attain clinical remission even after 2 doses of 1g RTX.

Conclusion:

- [1] Patients with early arthritis (diagnosis made within 1 year) and who were DMARD naïve had an excellent response to Rituximab.
- [2] Complete remission was observed in more patients the 1g compared to 500mg group.
- [3] Reduction in CD19 & CD20 was associated with significant reduction in the SDAI score.
- [4] There was no significant reduction of CD19 & CD20 with 500mg dose of Rituximab where either a partial remission or mild flare was observed.
- [5] There was reduction in the lung involvement to less than 20%(CT) in few patients with 1g dose.
- [6] Double negative Rheumatoid arthritis poorly responded to Rituximab.
- [7] The positive effects of 1g Rituximab could be noted up to 24 months.
- [8] Flare of RA was associated with significant increase in CD19 & CD20.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3794

AB0236

DOWN-TITRATION STRATEGY OF TUMOR NECROSIS FACTOR-INHIBITOR AGENTS FOR RHEUMATOID ARTHRITIS IN TUNISIA

K. Saadaoui¹, H. Sahli¹, S. Boussaid¹, J. Samia¹, R. Sonia¹, C. Elhem¹, E. Mohammed¹. ¹La Rabta Hospital, Rheumatology, Tunis, Tunisia

Background: Tumor necrosis factor (TNF) blocking agents are effective in treating rheumatoid arthritis, but they are associated with several adverse effects and high costs. Some studies have assessed the effectiveness of down-titration compared with continuation of standard dose.

Objectives: The aim of our study is to assess dose tapering in Tunisia.

Methods: A retrospective study including 170 rheumatoid arthritis patients treated by TNF blocker agent and with either low disease activity or remission (ACR/EULAR criteria). Two groups were compared, in the first group (G1) the interval of TNFi administration was extended, in the second group (G2) the standard dose and rhythm of administration were maintained.

Results: The TNFi tapering group (G1) included 96 persons whereas the group having the same drug administration rhythm (G2) included 74 case. The baseline age of the down-dosing drug group was 56.6 ± 12.6 years versus 52.9 ± 11.6 years in the other group (p = 0.046) and the average disease duration were respectively 12.3 ± 7.2 years versus 11.2 ± 6 years (p = 0.346). Women represented 88.5% in G1 versus 93% in G2 (p = 0.298). Rheumatoid Factors and ACPA were positive respectively in (85.5% versus 83.8; p = 0.748) and (76.4% versus 67.8%; p = 0.309). Etanercept, adalimumab, certolizumab pegol and infliximab were respectively used in 84.4%, 9.4%, 4.2% and 2.1% cases (G1), whereas they were used in 48.6%, 16.2%, 27% and 8.1% cases in the second group (G2). In the TNFi down dosing group, methotrexate was associated to TNFi in 74% cases while 71.6% of patient received methotrexate in the standard rhythm of administration group (p = 0.734). Corticosteroids were used by 40.6% of patients in G1 vs. 56.8% of patients in G2 (p = 0.037). The average DAS₂₈ at baseline was 5.91 ± 0.81 (G1) versus 5.95 ± 0.80 (G2) (p = 0.759). There was no statistically significant difference between the two groups for rates of TNFi withdrawal (p = 0.798). In fact, TNFi was interrupted due to inefficacy for 17 patients (17.7%) in the down-dosing group versus 12 patients (16.2%) in the other group.

Conclusion: Our study add evidence that TNFi drugs tapering could be equivalent to maintenance strategy. This could be beneficial to decrease the risk of adverse effect or reduce costs. Further studies are needed to confirm those results and identify patients who could benefit of TNFi administration rhythm step-down.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3804

AB0237

INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB AND ANTI-TNF INHIBITOR

N. Zehraoui¹, R. Benaziez Boutaleb¹, H. Hafirassou¹, F. Mechid¹, N. Bahaz¹, C. Makhloufi-Dahou¹. ¹Mohamed Lamine Debaghine University Hospital, Rheumatology, Algiers, Algeria

Background: Biological therapies have significantly improved the management of rheumatoid arthritis (RA). These molecules are very effective, but are known for their specific risks, especially infectious. It depends on several factors including the type of molecule used.

Objectives: The objective of our study is to compare the rate of infection in RA patients treated with rituximab and anti-TNFα.

Methods: Prospective, observational, monocentric study. Were included RA patients (ACR / EULAR 2010 criteria) treated with rituximab and anti-TNFα (adalimumab, infliximab and Etanercept) after inadequate response to DMARDs. Demographic characteristics, comorbidities, association with methotrexate and corticosteroids were collected and compared for each group.

The number, type and severity of the infections in both cases were noted.

SPSS (Statistical Package for Social Science) was used for data analysis.

Results: 40 RA patients treated with rituximab and 31 patients who received anti-TNFα were included.

Patient characteristics and Comparison of rate of infection in RA patients between the two groups are summarized in Table 1

Table 1.

Parameters	Rituximab	Anti-TNFα	p
Number of patients	40	31	
Average age (years)	56,28	46,06	0,01
Sexratio	0,14	0,11	0,7
Average duration of evolution (years)	15,83	13,74	0,3
Patients under corticosteroid (%)	97,5	87,1	0,08
Average corticosteroid dose patients under methotrexate (%)	6,41	5,48	0,3
Diabetes (%)	37,5	45,2	0,5
Patients with infection (%)	20	16,1	0,7
Number of infections	32,5	51,6	0,1
Number of serious infections	18	24	0,4
	5	0	0,04

Conclusion: The rate of infections in patients with RA treated with rituximab or anti-TNF was similar. However, the infections observed were more serious in patients with RA treated with rituximab

REFERENCES:

- [1] Fabiola Atzeni MD PhD and al. Infections and Biological Therapy in Patients with Rheumatic Diseases. IMAJ . VOL 18. march-APRIL 2016.
- [2] Huifeng Yun and al. Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. ARTHRITIS & RHEUMATOLOGY. Vol. 68, No. 1, January 2016, pp 56–66.
- [3] Manjari Lahiri and al. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Practice & Research Clinical Rheumatology (2015) 1-16.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3854

AB0238

SECOND BIOLOGICAL DMARD THERAPY IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT ANALYSIS

K. Saadaoui¹, H. Sahli¹, S. Jemmali¹, S. Boussaid¹, S. Rekik¹, E. Cheour¹, M. Elleuch¹. ¹La Rabta Hospital, Rheumatology, Tunis, Tunisia

Background: The development of biologic disease modifying antirheumatic drugs (bDMARD) has dramatically improved the management of rheumatoid arthritis (RA). However, some patients did not respond or partially respond to biologic agents. Management of first bDMARD failure may involve another biotherapy.

Objectives: The aim of our study is to assess the efficacy of second line biologic as well as survival rates of 2nd line biotherapy in RA.

Methods: This is a retrospective study based on Tunisian data including 374 RA patients treated with biologic agent from 2014 and followed until December 2018.

Results: Tumor necrosis factor inhibitor (TNFi) was the most prescribed class as first-line therapy with 86.4% patients (Etanercept: ETA 54%; adalimumab: ADA 13.6%; certolizumab pegol: CZP 12.8% and infliximab: IFX 5.9%), IL-6 inhibitor (Tocilizumab: TCZ) and anti-CD 20 (Rituximab: RTX) were given respectively to 6.4% and 7.2% cases. The first biotherapy was discontinued for 146 patients (39%). Of these, 79 patients (21.1%) received a second bDMARD (mean age 52.6 ± 11.8; sex ratio = 0.12; ETA 17.7%, ADA 7.6%, CZP 41.8%, IFX 1.3%, TCZ 24.1% and RTX 7.6%). Average DAS₂₈ at second line biotherapy initiation was 5.93 ±